宋天豹, 王建军, 孙小虎, 王保信, 陈绍华, 李国明, 吕建男. 副乳癌和常规胸部乳腺癌HES1、HER2表达差异及临床病理特征分析[J]. 蚌埠医学院学报, 2021, 46(5): 611-615. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.013
    引用本文: 宋天豹, 王建军, 孙小虎, 王保信, 陈绍华, 李国明, 吕建男. 副乳癌和常规胸部乳腺癌HES1、HER2表达差异及临床病理特征分析[J]. 蚌埠医学院学报, 2021, 46(5): 611-615. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.013
    SONG Tian-bao, WANG Jian-jun, SUN Xiao-hu, WANG Bao-xin, CHEN Shao-hua, LI Guo-ming, LÜ Jian-nan. Differential expression of HES1 and HER2 and analysis of clinicopathological features between accessory breast cancer and routine mammary cancer[J]. Journal of Bengbu Medical College, 2021, 46(5): 611-615. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.013
    Citation: SONG Tian-bao, WANG Jian-jun, SUN Xiao-hu, WANG Bao-xin, CHEN Shao-hua, LI Guo-ming, LÜ Jian-nan. Differential expression of HES1 and HER2 and analysis of clinicopathological features between accessory breast cancer and routine mammary cancer[J]. Journal of Bengbu Medical College, 2021, 46(5): 611-615. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.013

    副乳癌和常规胸部乳腺癌HES1、HER2表达差异及临床病理特征分析

    Differential expression of HES1 and HER2 and analysis of clinicopathological features between accessory breast cancer and routine mammary cancer

    • 摘要:
      目的探讨副乳癌(ABC)和常规胸部乳腺癌(MC)转录因子发状分裂相关增强子1(HES1)、人类表皮生长因子受体2(HER2)表达差异及其与临床病理特征的关系。
      方法回顾性分析30例ABC和30例MC病人的临床资料、病理资料和肿瘤组织HES1、HER2表达情况及随访资料,并进行统计分析。
      结果ABC组HES1、HER2阳性表达率分别为30.00%、53.33%,MC组为40.00%、40.00%,2组HES1和HER2阳性率差异均无统计学意义(P>0.05)。ABC组和MC组病人HES1阳性表达率在不同病理类型、组织学分级、临床分期和是否淋巴结转移、三阴乳腺癌间差异均有统计学意义(P < 0.05~P < 0.01),ABC组HES1阳性表达率在是否复发病人间差异亦有统计学意义(P < 0.05)。ABC病人HER2阳性表达率在不同病理类型、组织学分级、临床分期和是否三阴乳腺癌及复发间差异均有统计学意义(P < 0.05~P < 0.01);MC病人HER2阳性表达率在不同病理类型、临床分期和是否淋巴结转移、三阴乳腺癌间差异均有统计学意义(P < 0.01)。
      结论术前HES1、HER2阳性表达率可一定程度上反映ABC、MC病人病理特征,为合理手术方案的选择提供参考。

       

      Abstract:
      ObjectiveTo investigate the differences in the expression of hairy and enhancer of split 1(HES1) and human epidermal growth factor receptor 2(HER2) in accessory breast cancer(ABC) and routine mammary cancer(MC) and their relationship with clinicopathological features.
      MethodsThe clinical data, pathological data, expression of HES1 and HER2 in cancer tissues and follow-up data of 30 patients with ABC and 30 patients with MC were analyzed retrospectively and evaluated statistically.
      ResultsThe positive expression rates of HES1 and HER2 in ABC group were 30.00% and 53.33%, respectively, which were 40.00% and 40.00% in MC group, respectively, and the difference of which was not statistically significant(P>0.05).There were significant differences in the positive expression rate of HES1 between ABC group and MC group in different pathological type, histological grades, clinical stage, lymph node metastasis and triple negative breast cancer(P < 0.05 to P < 0.01).The positive expression rate of HES1 in ABC group was also statistically significant between patients with recurrence or not(P < 0.05).The positive expression rate of HER2 in ABC patients was statistically significant among different pathological type, histological grade, clinical stage, triple negative breast cancer and recurrence or not(P < 0.05 to P < 0.01).The positive expression rate of HER2 in MC patients was statistically significant among different pathological type, clinical stage, lymph node metastasis or not and triple negative breast cancer(P < 0.01).
      ConclusionsThe positive expression rates of HES1 and HER2 before surgery can reflect the pathological features of ABC and MC patients to a certain extent, and provide reference for the selection of reasonable surgical plans.

       

    /

    返回文章
    返回